6HFRQG$QQRXQFHPHQW 6FLHQFHWR0DUNHW $'LVFXVVLRQDQG3DUWQHULQJ&RQIHUHQFH IRU([SHUWVIURP$FDGHPLD%LRWHFKQRORJ\ DQG3KDUPDFHXWLFDO,QGXVWU\

Transcription

1 6HFRQG$QQRXQFHPHQW 6FLHQFHWR0DUNHW $'LVFXVVLRQDQG3DUWQHULQJ&RQIHUHQFH IRU([SHUWVIURP$FDGHPLD%LRWHFKQRORJ\ DQG3KDUPDFHXWLFDO,QGXVWU\ 2FWREHU± &RQYHQWLRQ&HQWHU+DQQRYHU*HUPDQ\ 2UJDQLVHGE\ WKH(XURSHDQ$VVRFLDWLRQRI3KDUPD%LRWHFKQRORJ\($3% LQFRRSHUDWLRQZLWK%,27(&+1,&$

2 2UJDQLVHU The European Association of Pharma Biotechnology is a non-profit association and the representative and central network to promote and develop Pharma Biotechnology in Europe, linking academia, industries and regulatory bodies. It is dedicated to the advancement of biotechnology in pharmaceutical sciences, specifically as applied to industrial materials, processes, products and their associated problems. Its members constitute scientists employed in industry, government and university laboratories, biotech companies and scientific organisations. 6FLHQWLILFDQG3ODQQLQJ&RPPLWWHH Dr. Karoline Bechtold-Peters (Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, GER) Dr. Fabio Carli (Università di Trieste, ITA) Dr. Jörg Knäblein (Bayer Schering AG, Berlin, GER) Dr. Marion Kronabel (EAPB Managing Director, Heidelberg, GER) Dr. Henrik L. Luessen (Tytonis BV, Alkmaar, NED) Dr. Barry D. Moore (XstalBiol, Glasgow, GBR) Dr. Inge Mühldorfer (Rentschler Biotechnologie GmbH, Laupheim, GER) Prof. Dr. Rainer Müller (Freie Univerisität Berlin, GER) Dr. Sven Stegemann (Capsugel AG, Bornem, BEL) Prof. Dr. Heiko E. von der Leyen (Hannover Clinical Trial Center GmbH, Hannover, GER) Dr. Wieland W. Wolf (Rentschler Biotechnologie GmbH, Laupheim, GER) &RRSHUDWLRQSDUWQHU "Turning ideas into value" this is the mission statement of BIOTECHNICA The European flagship event for biotechnology takes place from 6 to 8 October 2009 in Hannover. It embraces every segment of biotechnology - from basic biotechnology and equipment, bio-informatics and services to the five major areas of application: pharmaceuticals/medicine, food, agriculture, the chemical industry and the environment. 2/7

3 $LP 6FRSH As a European event, the Science to Market EAPB Conference aims to promote partnership between academic settings and industry. The goal is to enhance the economical output of scientific research and direct them into marketable technologies and biopharmaceutical products. Recent biotechnological developments that may be of economic interest shall be identified and transfer of the academic know-how into product development shall be facilitated. Therefore, European academic research scientists from universities and research institutions as well as representatives of the biotech and pharmaceutical industry are invited to exchange ideas that will lead to successful co-operations. )RUPDW To achieve the conference goals, the congress offers plenary lectures on state-of-the-art technologies and findings in biopharmaceutical developments as well as poster presentations on current projects and networking opportunities. 3RVWHU&RQWULEXWLRQV Poster presentations on scientific pharmaceutical drug projects and novel technologies in the fields of biotechnology and pharmaceutical drug development are welcome. The posters shall be presented by RUDO ILYHPLQXWHVSUHVHQWDWLRQV (two slides on science and business opportunity) and in addition by traditional posters (paper size A0 high format) to facilitate networking between academic/ research and industrial partners. You are kindly invited to submit your abstract electronically by 6HSWHPEHU via to the conference manager Dr. Inge Mühldorfer (inge.muehldorfer@rentschler.de), indicating the preferred poster session. Poster session 1: Therapeutics and diagnostics (1a) Novel biopharmaceuticals and diagnostics (1b) 2nd generation biopharmaceuticals (1c) Novel vaccines and gene therapy developments Poster session 2: Novel technologies (2a) Novel biopharmaceutical drug formats (2b) Novel Up-and Downstream developments (2c) Novel biopharmaceutical drug delivery and analytical tools 5HTXLUHPHQWVIRURQHSDJHDEVWUDFW Please provide a one-page abstract typed in a single-spaced format using a 12-point serif font (e. g. Arial, Times New Roman, etc.). Do not format the document using underlining, italics, or right justification. Do not use sub/superscripts or Greek lettering (i.e. spell out alpha, beta, etc.). Please save it as a Microsoft Word (*.doc) document or an ASCII (*.txt) text file. Please include the following items: 3/7

4 7LWOHThe title that you propose for your presentation as you would like it to appear in the program which will be posted at the conference WEB site and on the brochure. $XWKRUVDQGSUHVHQWHUName/title of author(s). The individual who will make the presentation shall be marked.,qvwlwxwlrq&rpsdq\name of the institution/company represented by the authors. The contact address of the presenter shall be indicated. $EVWUDFWis usually between 150 to 300 words long. With the registration the authors agree with the publication of their abstracts on the EAPB website. 6SRQVRUVKLS2SWLRQV Any sponsoring of the conference is welcome. For every 1000 ¼ VSRQVRULQJ \RX ZLOO receive free entrance for one participant. For a total of either 1000 ¼¼RU¼ sponsoring, you will be indicated as silver, gold or platinum sponsor, respectively, in the conference programme, on the EAPB website, and on the conference banner. If you decide to become a sponsor, please contact the Managing Director of the EAPB, Dr. Marion Kronabel (Phone: + 49(0) ; Marion.kronabel@eapb.org) 5HJLVWUDWLRQ To register for Science to Market please visit the website of BIOTECHNICA and submit one registration form per participant. From the registration form you will see the conditions for participation. - Participation on October 6 and 7, Trade fair admission tickets - Coffee Breaks - Social event on October 6, 2009 Alterations to your registration must be made in writing and sent to the Conference Secretariat. &RQIHUHQFH5HJLVWUDWLRQ)HH 5DWH ($3%()% PHPEHUVUDWH,QGXVWU\ 470 EUR 435 EUR $FDGHPLD 235 EUR 200 EUR 3RVWHU RQHSHUVRQSRVWHU SUHVHQWHU 150 EUR 135 EUR 4/7

5 *HQHUDO,QIRUPDWLRQ &RQIHUHQFH%DGJH0DWHULDO Each participant will receive a name badge and a full set of conference material upon your arrival at the Registration Desk within the Convention Center in Hannover. For security reasons all participants are requested to wear their name badge during all the conference activities. 'LVFODLPHU/LDELOLW\ The organising Committee and the Conference Secretariat accept no liability for any injuries/losses incurred by participants and/or accompanying persons, nor loss of, or damage to, any luggage and/or personal belongings. (QWUDQFH7LFNHW&RQILUPDWLRQ You will receive your BIOTECHNICA Conference ticket together with your confirmation of participation upon the reception of payment. You will find detailed information about your payment possibilities within the registration form. /DQJXDJH English will be the language of the congress. No simultaneous translation will be provided. 'DWH 9HQXH October 6 7, 2009 Messegelände Hannover GERMANY This conference will take place in parallel with BIOTECHNICA th International Trade Fair for Biotechnology ( :HEVLWHV For the latest information about the Conference, please visit the Conference Website of the EAPB online at: 5/7

6 &RQWDFWV EAPB President Dr. Wieland W. Wolf EAPB Conference Manager Dr. Inge Mühldorfer Phone: +49(0) EAPB Managing Director Dr. Marion Kronabel Phone: + 49(0) Marion.kronabel@eapb.org 'HXWVFKH0HVVH Susan Canisius Messegelände Hannover Germany Phone: +49(0) Fax: +49(0) susan.canisius@messe.de Website: 6/7

7 3URJUDPPH 7XHVGD\2FWREHUWK 08:30 09:00 5HJLVWUDWLRQ 09:00 09:15 :HOFRPH,QWURGXFWLRQ 2SHQLQJ UHPDUNV Wieland W. Wolf, President of the EAPB, Rentschler Biotechnologie GmbH, Laupheim (GER) 09:15 09:45 7UHDWPHQWRIFDQFHUE\WULIXQFWLRQDODQWLERGLHV Horst Lindhofer, Trion Pharma GmbH, Munich (GER) 09:50 10:20 %L7(DQWLERG\SODWIRUP Patrick A. Baeuerle, Micromet GmbH, Munich (GER) &RIIHH%UHDN 10:50 11:20 3URGXFWLRQRIWKHUDSHXWLFDQWLERG\IUDJPHQWV John Liddell, Head of Process Science, Avecia Biologics, Billingham (GBR) 11:25 11:55,QGXFHGSOXULSRWHQWVWHPFHOOVIRUVWXGLHVRIGLVHDVHV Tobias Cantz, MPI Münster, Medizinische Hochschule Hannover (GER) /XQFK%UHDN 14:00 14:30 51$LQWHUIHUHQFHDVDQDQWLYLUDODSSURDFK Ben Berkhout, University of Amsterdam (NED) 14:30 15:00 $QWLVHQVHGUXJVIRUWKHWUHDWPHQWRIFDQFHUGLVHDVHV Karl-Hermann Schlingensiepen, Antisense Pharma GmbH, Regensburg (GER) &RIIHH%UHDN 15:15 17:00 2UDOSRVWHUSUHVHQWDWLRQV 17:00 18:00 1HWZRUNLQJDWSRVWHUERDUGV 18:00 19:00 6SHFLDONH\QRWHOHFWXUH +RZGRZHVWD\KHDOWK\"'U'DUZLQH[SODLQVRXUHYROXWLRQDU\KHULWDJH Ernst Peter Fischer, University of Konstanz (GER) 19:00 21:00 6RFLDO(YHQW :HGQHVGD\2FWREHUWK 08:30 09:00 5HJLVWUDWLRQ 09:00 09:30 'LDJQRVLVEDVHGRQDXWRDQWLERGLHV Stefan Müllner, Protagen AG, Dortmund (GER) 09:35 10:05 +RZWRDYRLGGRZQVWUHDPERWWOHQHFNV Alois Jungbauer, University of Natural Ressources and Applied Life Sciences, Vienna (AUT) &RIIHH%UHDN 10:20 10:50 0XOWLYDULDWHDQDO\VLVRISURWHLQSURGXFWLRQSURFHVVHV Dethardt Müller, Rentschler Biotechnologie, Laupheim (GER) 10:55 11:15 5HFRPELQDQW YDFFLQHV &KDOOHQJHV LQ SURGXFWLRQ IRUPXODWLRQ DQG FKDUDFWHUL]DWLRQ Robert Schlegl, Intercell AG, Vienna (AUT) 11:20 13:00 2UDOSRVWHUSUHVHQWDWLRQV 13:00 13:15 &ORVLQJUHPDUNV 13:15 14:00 1HWZRUNLQJDWSRVWHUERDUGV 7/7